Pharmacokinetics in children

The results of pharmacokinetic studies were similar in adults and adolescents. The amount of available zolmitriptan is the same or slightly lower in adolescents compared to adults. Accordingly, the amount of the available active metabolite is slightly increased. The differences are probably not clinically not clinically significant.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The type and severity of side effects in children were comparable to those in adults. However, no statements can be made on the frequencies.(SmPC 

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

• NERVOUS SYSTEM
• ANALGESICS

ANTIMIGRAINE PREPARATIONS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Reference

1. Grünenthal GmbH, SmPC AscoTop ® Nasal 5 mg/Dosis Nasenspray, Lösung (54619.01.00), 06/2023

Changes

Therapeutic Drug Monitoring

Overdose